| Summary of Significant Accounting Policies | Financial Statement Presentation The preparation of the financial statements in conformity with U.S.
generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect reported
amounts and related disclosures. Actual results could differ from these estimates. Certain prior year amounts have been reclassified
to conform to current year presentation. Pursuant to guidance in accounting standard codification (“ASC”)
205-20, Presentation of Financial Statements, and ASC 360-10-45-9 to 14, Property, Plant and Equipment, regarding when the results
of operations of a component of an entity that is classified as held for sale would be reported as a discontinued operation in
the financial statements of the entity. The Company determined that it met the threshold for reporting discontinued operations
due to a strategic business shift having a major effect on an entity's operations and financial results. On February 7, 2018, the Company announced that it entered into the
Purchase Agreement with FamilyCord. The sale of substantially all of the Company’s assets occurred on May 17, 2018. For this
reason, the results of operations for the cord blood and cord tissue stem cell operations have been reclassified into discontinued
operations. Basis of Consolidation The consolidated financial statements include the accounts of CBAI
and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated upon consolidation. Estimates The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ materially
from those estimates. Cash Cash and cash equivalents include cash on hand, deposits in banks
with maturities of three months or less, and all highly liquid investments which are unrestricted as to withdrawal or use, and
which have original maturities of three months or less at the time of purchase. The Company maintains cash and cash equivalents at several financial
institutions. The value of cash and cash equivalents held by the Company at a bank in excess of federally insured limits was $11,282,312
during the period ended December 31, 2019. Accounts Receivable Accounts receivable consist of the amounts due for facilitating the
processing and storage of umbilical cord blood and cord tissue, and birth tissue procurement services. Accounts
receivable relating to deferred revenues are netted against deferred revenue for presentation purposes. The allowance for doubtful
accounts is estimated based upon historical experience. The allowance is reviewed quarterly and adjusted for accounts deemed uncollectible
by management. Amounts are written off when all collection efforts have failed. The Company wrote off $0.00 and $10,220 in bad
debt expense during the years ended December 31, 2019 and 2018, respectively. Property and Equipment Property and equipment are stated at cost less accumulated depreciation.
Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. Routine maintenance and repairs
are charged to expense as incurred while major replacement and improvements are capitalized as additions to the related assets.
Sales and disposals of assets are recorded by removing the cost and accumulated depreciation from the related asset and accumulated
depreciation accounts with any gain or loss credited or charged to income upon disposition. Intangible Assets (related to cord blood and cord tissue stem
cell storage business) Intangible assets consist primarily of customer contracts and relationships
as part of the acquisition of the CorCell and CureSource assets in 2007. During 2011 the Company also foreclosed and acquired assets
from NeoCells, a subsidiary of ViviCells, as satisfaction of outstanding receivables from ViviCells. Intangible assets are stated
at cost. Amortization of intangible assets is computed using the sum of the years’ digits method, over an estimated useful
life of 18 years. Amortization expense included in the discontinued operations for the years ended December 31, 2019 and 2018 was
$0.00 and $27,345 respectively. Notes Receivable (related to cord blood and cord tissue stem cell
storage business) Notes receivable consists of the notes due from Biocordcell Argentina
S.A. (BioCells). The notes receivable are recorded at carrying-value on the financial statements. For note receivable from BioCells, since the Company agreed to finance
the sale of the shares in BioCells at no stated interest, in accordance with ASC 500, the interest method was applied using a 6%
borrowing rate. The Company recorded an unamortized discount based on the 6% borrowing rate and the discount is amortized throughout
the life of the note. Deferred Revenue (related to cord blood and cord tissue stem cell
storage business) Deferred revenue consists of payments for enrollment in the program
and processing of umbilical cord blood and cord tissue by customers whose samples have not yet been collected, as well as the pro-rata
share of annual storage fees for customers whose samples were stored during the year. Valuation of Derivative Instruments ASC 815-40 requires that embedded derivative instruments be bifurcated
and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC
815-40-15 to determine whether they should be considered a derivative liability and measured at their fair value for accounting
purposes. In determining the appropriate fair value, the Company uses the Binomial option pricing formula and present value pricing.
At December 31, 2019 and December 31, 2018, the Company adjusted its derivative liability to its fair value, and reflected the
change in fair value, in its consolidated statements of operations. Revenue Recognition (related to cord blood and cord tissue stem
cell storage business) In May 2014, the Financial Accounting Standards Board (“FASB”)
issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). Under the provisions of Accounting Standards Update (“ASU”)
2014-09, entities should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects
the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, ASU 2014-09
requires new and enhanced disclosures. Companies may adopt the new standard either using the full retrospective approach, a modified
retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted ASC 606 effective
January 1, 2018 using the full retrospective approach. The adoption of ASU 2014-09 did not have any material impact on the Company’s
consolidated financial position, results of operations, equity or cash flows. Cost of Services Costs are incurred as umbilical cord blood, cord tissue and
birth tissue are collected. These costs include the transportation of the umbilical cord blood, cord tissue and birthing tissue
from the hospital, direct material and labor, costs for processing and cryogenic storage of new samples by a third party laboratory,
collection kit materials and allocated rent, utility and general administrative expenses. The Company expenses costs in the period
incurred. Income Taxes The Company follows the asset and liability method of accounting
for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized as income in the period that included the enactment date. The measurement of deferred tax assets is
reduced, if necessary, by a valuation allowance based on the portion of tax benefits that more likely than not will not be realized. The Company follows guidance issued by the FASB with regard to its
accounting for uncertainty in income taxes recognized in the financial statements. Such guidance prescribes a recognition threshold
of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or
expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that
a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the
tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax
benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2019 and 2018. The Company files
income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. Accounting for Stock Option Plan The Company follows the provisions of Accounting Standards Codification
(“ASC”) 718, “Accounting for Stock-based Compensation”), which requires recognition in the consolidated
financial statements of the cost of employee and director services received in exchange for an award of equity instruments over
the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period).
ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the
grant-date fair value of the award. Pursuant to ASC Topic 505-50, for share-based
payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The
expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation
expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting
date. Earnings (Loss) Per Share Basic earnings per share (EPS) is computed by dividing net income
available to common stockholders by the weighted average number of common shares outstanding. Diluted EPS is similar
to basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional
common shares that would have been outstanding if the dilutive potential common shares had been exercised. The Company’s
common equivalent shares are excluded from the computation of diluted EPS if the effect is anti-dilutive. The
diluted weighted average common shares outstanding are 1,272,066,146 and as
of December 31, 2019 and 2018, respectively. Concentration of Risk Credit risk represents the accounting loss that would be recognized
at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk (whether on or
off balance sheet) that arise from financial instruments exist for groups of customers or counterparties when they have similar
economic characteristics that would cause their ability to meet their contractual obligations to be similarly affected by changes
in economic or other conditions described below. Relationships and agreements which could potentially expose the Company
to concentrations of credit risk consist of the use of one source for the processing and storage of all umbilical cord blood and
one source for the development and maintenance of a website. The Company believes that alternative sources are available for each
of these concentrations. Financial instruments that subject the Company to credit risk could
consist of cash balances maintained in excess of federal depository insurance limits. The Company maintains its cash and cash equivalent
balances with high credit quality financial institutions. At times, cash and cash equivalent balances may be in excess of Federal
Deposit Insurance Corporation limits, and as of December 31, 2019, this was the case. To date, the Company has not experienced
any such losses. Fair Value Measurements Assets and liabilities recorded at fair value in the consolidated
balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level
inputs, as defined by ASC 820, are as follows:
● Level 1 – quoted prices in active markets for identical assets or liabilities.
● Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.
● Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. There were no financial instruments measured on a recurring basis
as of December 31, 2019 and 2018 and on a non-recurring basis for any of the periods presented. For certain of the Company’s financial instruments, including
cash, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and deferred revenues, the
carrying amounts approximate fair value due to their short maturities. The carrying amounts of the Company’s notes receivable
and notes payable approximates fair value based on the prevailing interest rates. Comprehensive Income and Loss The Company had no items that would be classified as other comprehensive
income or loss for the years ended December 31, 2019 and 2018. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”)
issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”
(ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective
Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting
Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements
and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to
depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects
to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may
adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients,
or a cumulative effect upon adoption approach. The Company adopted ASC 606 effective January 1, 2018 using the full retrospective
approach. The adoption of ASU 2014-09 did not have any material impact on the Company’s consolidated financial position,
results of operations, equity or cash flows. In August 2016, the FASB issued ASU No. 2016-15, Statement
of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU No. 2017-01, Business Combinations
(Topic 805): Clarifying the Definition of a Business. This new standard clarifies the definition of a business and provides a screen
to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all
of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar
identifiable assets, the set is not a business. This new standard was effective for the Company on January 1, 2018, and there
was no impact as a result of adopting this ASU on our financial statements and related disclosures. In February 2016, the FASB
issued ASU No. 2016-02, Leases (Topic 842), under
the new guidance, lessor accounting is largely unchanged. Certain targeted improvements were made to align, where necessary, lessor
accounting with the lessee accounting model and Topic 606, Revenue from Contracts with Customers. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement
(Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. This new standard removes,
adds and modifies certain disclosure requirements for fair value measurements in Topic 820. The Company will no longer
be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, and the
valuation processes of Level 3 fair value measurements. However, the Company will be required to additionally disclose the changes
in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements, and the range
and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. The
ASU is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The
amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual
period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented
upon their effective date. The Company is permitted to early adopt either the entire ASU or only the provisions that eliminate
or modify the requirements. The Company evaluated the impact of this pronouncement and concluded that the guidance does not
have a material impact on its financial position and results of operations. In December 2019, the FASB issued ASU No. 2019-12, Simplifying
the Accounting for Income Taxes |
